XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration

Abstract Introduction XTEND (NCT03939767) is a multicenter, observational, prospective study of patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in routine clinical practice. The study aims to examine treatment outcomes of proactive intravitreal aflibercept (IVT-AFL)...

Full description

Bibliographic Details
Main Authors: Jean-François Korobelnik, Varun Chaudhary, Paul Mitchell, Se Woong Kang, Ramin Tadayoni, Helmut Allmeier, JinKyung Lee, Xin Zhang, Tobias Machewitz, Clare Bailey
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-01-01
Series:Ophthalmology and Therapy
Subjects:
Aflibercept
Age-related macular degeneration
Clinical trial
Intravitreal
Macula
Neovascularization
Online Access:https://doi.org/10.1007/s40123-023-00867-x

Internet

https://doi.org/10.1007/s40123-023-00867-x

Similar Items